Cardiovascular disease (CVD) is the leading cause of death worldwide, accounting for one in three deaths globally. Existing treatments are often associated with significant side effects, limiting their use and reducing patient adherence. There is a large unmet need for new and innovative therapies that are safe, effective, and broad-spectrum.

Your compound is a promising candidate to meet this unmet need. It has shown significant efficacy in preclinical and clinical studies, demonstrating the potential to improve outcomes for patients with a wide range of CVD conditions, including heart failure, coronary artery disease, and stroke. Your compound has a favorable safety profile, with a low incidence of adverse events. Additionally, it has broad-spectrum activity, targeting the underlying causes of CVD and reducing the risk of complications

Shen helps you navigate the complex challenges that have prevented the development and approval of cardiovascular drugs

  • Shen helps pharmaceutical companies overcome the challenges that have hindered the development and approval of cardiovascular drugs by:

    • Designing efficient clinical trials
    • Recruiting diverse patient populations
    • Navigating the regulatory landscape

    Here are some specific examples of how Shen has helped clients:

    • Designed a clinical trial for a new heart failure drug that was significantly more efficient than traditional trials
    • Recruited a diverse patient population for a clinical trial of a new coronary artery disease drug
    • Helped a client navigate the regulatory landscape for a new high cholesterol drug

    Shen’s commitment to helping pharmaceutical companies develop and approve new cardiovascular drugs is making a real difference in the lives of patients around the world.

Driving better healthcare decisions and improving patient lives

In the era of value-based medicine, it’s crucial for companies to do more than prove the efficacy of their drugs. They must establish how their drugs compare to competitors on multiple fronts, including payer reimbursement and the patient experience.

Shen’s cardiovascular program has conducted CVD outcome studies over the past five years, involving numerous sites and patients, including those with comorbid conditions such as type 2 diabetes, acute coronary syndrome, hypertension, hyperlipidemia/dyslipidemia, and obesity.

Our team of medical, therapeutic, and operational experts excels at strategic planning and execution for CVD outcomes research. This includes:

1. Tailored Standard MedDRA queries designed specifically for major adverse cardiac events (MACE).
2. Cutting-edge analytics that provide customized insights and highlight potential risks.
3. A wealth of experience with various academic research organization (ARO) partnership models.
4. Regulatory experts who are well-versed in the ever-changing regulatory landscape.
5. Extensive experience in conducting global Type 1 and Type 2 diabetes trials.

Shen is your partner for navigating the complexities of showcasing your drug’s comparative value in the cardiovascular field, considering the evolving healthcare environment and a comprehensive range of parameters beyond drug efficacy.

Global reach to cardiovascular specialists and clinical trial sites

Shen Clinical Services provides the resources needed for large, multinational cardiovascular trials. Our international investigator network establishes and maintains relationships with global study sites to recruit patients efficiently and accurately.

Our network includes a diverse group of cardiologists from around the world. Our global team of clinical and medical professionals has experience conducting a wide range of cardiovascular studies, and we have a global network of dedicated research sites.

A full range of cardiovascular imaging services

Shen Clinical Services provides a full range of cardiovascular imaging services, including:

  • Echocardiography
  • Transesophageal echocardiography
  • Stress echocardiography
  • Nuclear cardiology
  • Cardiac computed tomography (CT)
  • Cardiac magnetic resonance imaging (MRI)

These services can be used to diagnose and monitor a wide range of cardiovascular conditions, including:

  • Coronary artery disease
  • Heart failure
  • Valvular heart disease
  • Cardiomyopathy
  • Congenital heart disease

Shen Clinical Services’ cardiovascular imaging services are performed by experienced and highly qualified cardiologists and radiologists. We use the latest imaging technology to provide our patients with the most accurate and up-to-date diagnosis and treatment possible. Collaborating with the sponsors with the highest quality, most efficient clinical study design, management and operations despite seasonal changes in individual countries, spans a broad range of indications.